These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 8858891)

  • 1. Cytochrome P450: genetic polymorphism and drug interactions.
    Belpaire FM; Bogaert MG
    Acta Clin Belg; 1996; 51(4):254-60. PubMed ID: 8858891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
    Brosen K
    Clin Pharmacokinet; 1990 Mar; 18(3):220-39. PubMed ID: 2182263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
    Yu AM; Idle JR; Gonzalez FJ
    Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).
    Sandwall P; Lo MW; Jonzon B; Dalén P; Furtek C; Ritter M; Alván G; McCrea J; Sjöqvist F
    Eur J Clin Pharmacol; 1999 Jun; 55(4):279-83. PubMed ID: 10424320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease.
    Tanaka E
    J Clin Pharm Ther; 1998 Jun; 23(3):161-70. PubMed ID: 9831966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
    Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
    Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
    Zanger UM; Raimundo S; Eichelbaum M
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs].
    Brøsen K
    Ugeskr Laeger; 1991 Feb; 153(6):417-22. PubMed ID: 2000644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update: genetic polymorphism of drug metabolizing enzymes in humans.
    Tanaka E
    J Clin Pharm Ther; 1999 Oct; 24(5):323-9. PubMed ID: 10583694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T; Price A
    Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism.
    Kroemer HK; Eichelbaum M
    Life Sci; 1995; 56(26):2285-98. PubMed ID: 7791516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms of genetic polymorphisms of drug metabolism.
    Meyer UA; Zanger UM
    Annu Rev Pharmacol Toxicol; 1997; 37():269-96. PubMed ID: 9131254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.
    Linder MW; Prough RA; Valdes R
    Clin Chem; 1997 Feb; 43(2):254-66. PubMed ID: 9023127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacogenetics of oxidation reactions of drugs].
    Jacqz-Aigrain E
    Arch Fr Pediatr; 1989 Jan; 46(1):59-65. PubMed ID: 2653266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
    Neafsey P; Ginsberg G; Hattis D; Sonawane B
    J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically determined adverse drug reactions involving metabolism.
    Lennard MS
    Drug Saf; 1993 Jul; 9(1):60-77. PubMed ID: 8347292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs.
    Stingl J; Viviani R
    J Intern Med; 2015 Feb; 277(2):167-177. PubMed ID: 25297512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
    Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M
    Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.